retatrutide take to work – new weight loss medication in development Doctor Explains How to Dose

Stay consistent, feel supported, and celebrate your progress

The SEMALEAN study followed 106 adults with obesity (mean BMI 46, mean age 52, roughly half meeting sarcopenic obesity criteria at baseline) on max-dose semaglutide for 12 months, with DXA and handgrip dynamometry at baseline, seven months, and twelve months

Retatrutide benefits stem from its unique status as a "triple agonist." While popular drugs like Ozempic mimic one hormone (GLP-1) and Mounjaro mimics two (GLP-1 and GIP), Retatrutide introduces a third player: Glucagon

Switching between GLP-1 compounds allows your provider to test which pathway combination works best for your unique genetics and symptom profile

However, as the first generic GLP-1 on the market, it should offer a significantly lower prices at a time when similar products are tripling their price points to locations outside the US